A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 09 May 2013
At a glance
- Drugs Pemetrexed (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 09 May 2013 Primary endpoint 'Time-to-disease-progression' has not been met.
- 18 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.